Candel Therapeutics, Inc.
CADL
$4.82
$0.0551.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -45.44% | -63.49% | -55.34% | -39.87% | -101.87% |
| Total Depreciation and Amortization | 3.13% | 6.65% | 11.43% | 16.37% | 23.39% |
| Total Amortization of Deferred Charges | -16.41% | -4.10% | -1.52% | -0.90% | 11.00% |
| Total Other Non-Cash Items | 803.92% | 2,620.33% | 2,583.89% | 166.41% | 121.34% |
| Change in Net Operating Assets | 165.90% | 154.72% | 72.79% | 110.39% | -839.44% |
| Cash from Operations | 21.09% | 15.06% | 9.97% | 6.79% | -8.99% |
| Capital Expenditure | 96.50% | 91.25% | 79.57% | 74.21% | 64.76% |
| Sale of Property, Plant, and Equipment | -- | -87.26% | -87.26% | -87.26% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.29% | 92.44% | 77.69% | 72.36% | 78.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 24,994.44% | 13,391.67% | 610.34% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 78,017.36% | 6,138.89% | 1,480.56% | -2,472.41% | -100.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.09% | 22.73% | 12.75% | 4.79% | -171.90% |